AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tetratherix Ltd

7.150

+0.2203.17%

Volume:59.39K

Turnover:418.19K

Market Cap:378.45M

PE:-38.90

High:7.340

Open:7.050

Low:6.750

Close:6.930

52wk High:8.080

52wk Low:3.090

Shares:52.93M

Float Shares:16.15M

Volume Ratio:1.69

T/O Rate:0.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.184

EPS(LYR):-0.184

ROE:-31.08%

ROA:-14.05%

PB:11.56

PE(LYR):-38.90

Loading ...

Overview Company News Filings

Tetratherix Begins Tetramatrix Product Revenue With First US Shipment

MT Newswires Live

Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise

MT Newswires Live

Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments

MT Newswires Live

Tetratherix Completes Share Purchase Plan

MT Newswires Live

Tetratherix Says Research Validation of Polymer Product Confirms Enabling of Direct Absorption into the Bloodstream

MT Newswires Live

BRIEF-Tetratherix Receives Firm Commitments For A$15 Million Placement At Issue Price Of A$6

Tetratherix Raises AU$15 Million Via Institutional Placement; Shares Tumble 6%

MT Newswires Live

Tetratherix - Receives Firm Commitments for a$15 Mln Placement at Issue Price of a$6

THOMSON REUTERS

Market Chatter: Tetratherix Seeks to Raise Around AU$15 Million Via Equity Raise, AFR Says

MT Newswires Live

BRIEF-Tetratherix Requests Trading Halt

A AU$90m Market Cap Boost Pleasing ToTetratherix Insiders

Simply Wall St.

Tetratherix Launches Precision Medicine Franchise, Signs $3 Million-a-Year Deal With Superpower Health

MT Newswires Live

ASX Today: RBA call looming, Iran War unchanged, gold @ US$5K flat – so XJO errs on side of caution

The Market Herald

This asx biotech company has piled on more than 25% after a big announcement

Tetratherix, which focuses on post-surgery skin healing, eyes new product: Nasal Ozempic

The Market Herald

BUZZ-Australia's Tetratherix rises on nasal delivery deal of GLP-1 in US market

Tetratherix Says Joint Venture Partner Completes Series A Funding Round to Progress Prostate Spacing Clinical Trial, Shares Jump 5%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/TTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","market":"AU","secType":"STK","nameCN":"Tetratherix Ltd","latestPrice":7.15,"timestamp":1788156720000,"preClose":6.93,"halted":0,"volume":59389,"delay":0,"changeRate":0.03174603174603184,"nameEN":"Tetratherix Ltd","floatShares":16151799,"shares":52929483,"eps":-0.1838,"marketStatus":"Not Yet Opened","change":0.22,"latestTime":"08-31 16:12:00 AEST","open":7.05,"high":7.34,"low":6.75,"amount":418191,"amplitude":0.085137,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1838,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"listingDate":1751119200000,"exchange":"ASX","adjPreClose":6.93,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.6853106710073644,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TTX.AU","preClose":6.93,"auctionPrice":7.15,"auctionVolume":1134,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156603760}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","floatShares":16151799,"roa":"-14.05%","roe":"-31.08%","lyrEps":-0.1838,"volumeRatio":1.6853106710073644,"shares":52929483,"dividePrice":0,"high":7.34,"amplitude":0.085137,"preClose":6.93,"low":6.75,"week52Low":3.09,"pbRate":"11.56","psRate":"98.00","week52High":8.08,"institutionHeld":0,"latestPrice":7.15,"eps":-0.1838,"divideRate":0,"volume":59389,"delay":0,"ttmEps":-0.1838,"open":7.05,"prevYearClose":3.28,"prevWeekClose":6.93,"prevMonthClose":7.15,"prevQuarterClose":6,"fiveDayClose":6.2,"twentyDayClose":7.7,"sixtyDayClose":5.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663618023","title":"Tetratherix Begins Tetramatrix Product Revenue With First US Shipment","url":"https://stock-news.laohu8.com/highlight/detail?id=2663618023","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663618023?lang=en_us&edition=fundamental","pubTime":"2026-08-31 08:50","pubTimestamp":1788137454,"startTime":"0","endTime":"0","summary":"Tetratherix  made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733736","title":"Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733736","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653733736?lang=en_us&edition=fundamental","pubTime":"2026-07-22 12:00","pubTimestamp":1784692834,"startTime":"0","endTime":"0","summary":"Tetratherix  received its first license fee revenue of $3 million in the June quarter as part of an exclusive research and development agreement with US consumer health group Superpower, according to a Wednesday filing with the Australian bourse.The fee revenue, combined with a net AU$14.7 million from a placement in May, left the company with a \"strong cash position\" of AU$34.4 million as of June 30, per the filing.The company closed the March quarter with AU$19.2 million of cash on hand, a previous filing showed.Tetratherix said it saw AU$19.3 million of cash inflows in the three months through June, bringing the total to AU$21.9 million for the full 2026 fiscal year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645300206","title":"Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2645300206","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645300206?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:57","pubTimestamp":1782187060,"startTime":"0","endTime":"0","summary":"Tetratherix  said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","VAP.AU","IIGF.AU","IOZ.AU","EIGA.AU","VAS.AU","STW.AU","SLF.AU","XAO.AU","E200.AU","OZR.AU","IISV.AU","JYNT","XJO.AU","XKO.AU","BEAR.AU","GIVE.AU","BK7067","IMLC.AU","BK4185","QRE.AU","GEAR.AU","ZYAU.AU","BBOZ.AU","DACE.AU","QFN.AU","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645145900","title":"Tetratherix Completes Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645145900","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645145900?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:33","pubTimestamp":1782088397,"startTime":"0","endTime":"0","summary":"Tetratherix  completed its share purchase plan, receiving applications totaling AU$639,644 at an issue price of AU$6 apiece, according to a Monday filing with the Australian bourse.Proceeds will be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and offer costs, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642454395","title":"Tetratherix Says Research Validation of Polymer Product Confirms Enabling of Direct Absorption into the Bloodstream","url":"https://stock-news.laohu8.com/highlight/detail?id=2642454395","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642454395?lang=en_us&edition=fundamental","pubTime":"2026-06-09 13:42","pubTimestamp":1780983779,"startTime":"0","endTime":"0","summary":"Tetratherix  said further research validation of the Tetramatrix platform polymer product confirmed it forms a protective, adhesive carrier on the nasal lining, guarding compounds from degradation and enabling direct absorption into the bloodstream, according to a Tuesday Australian bourse filing.The peer-reviewed study applied the product to insulin, confirming greater than 99% encapsulation, stability, protection from enzymatic degradation, and statistically superior compound delivery to the bloodstream and brain compared with unformulated insulin.Another study tested the product against bovine serum albumin and showed high encapsulation efficiency, stability over four weeks when refrigerated, zero cytotoxicity, greater deposition in the olfactory region, and a statistically significant increase in the tightening of nasal cell junctions.The studies were led by researchers at the Woolcock Institute of Medical Research, a Tetratherix research collaborator.Its shares rose 1% in recent t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638630095","title":"BRIEF-Tetratherix Receives Firm Commitments For A$15 Million Placement At Issue Price Of A$6","url":"https://stock-news.laohu8.com/highlight/detail?id=2638630095","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638630095?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:01","pubTimestamp":1779930104,"startTime":"0","endTime":"0","summary":"BRIEF-Tetratherix Receives Firm Commitments For A$15 Million Placement At Issue Price Of A$6May 28 (Reuters) - Tetratherix Ltd TTX.AX:RECEIVES FIRM COMMITMENTS FOR A$15 MILLION PLACEMENT AT ISSUE PRICE OF A$6Further company coverage: TTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN42416E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638963726","title":"Tetratherix Raises AU$15 Million Via Institutional Placement; Shares Tumble 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638963726","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638963726?lang=en_us&edition=fundamental","pubTime":"2026-05-28 08:25","pubTimestamp":1779927930,"startTime":"0","endTime":"0","summary":"Tetratherix  said it has received firm commitments from new and existing institutional investors to raise AU$15 million through a placement at AU$6 per share, representing a 2% discount to the 10-day volume-weighted average price of AU$6.12, according to a Thursday Australian bourse filing.The company said tranche 1 shares are anticipated to settle on June 3, while tranche 2 shares issued to directors are subject to shareholder approval at a general meeting.The company will also offer a share purchase plan  to existing eligible shareholders to raise a further AU$2 million, with proceeds from the placement and SPP to be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and transaction costs.The company's shares tumbled 6% in recent Thursday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632580","title":"Tetratherix - Receives Firm Commitments for a$15 Mln Placement at Issue Price of a$6","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638632580?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:24","pubTimestamp":1779924290,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN42416E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638598634","title":"Market Chatter: Tetratherix Seeks to Raise Around AU$15 Million Via Equity Raise, AFR Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2638598634","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638598634?lang=en_us&edition=fundamental","pubTime":"2026-05-26 13:12","pubTimestamp":1779772353,"startTime":"0","endTime":"0","summary":"Tetratherix  is reportedly looking to raise around AU$15 million from an equity raising at AU$6 per share, and it has brought in Barrenjoey Capital Partners and Morgans, the Australian Financial Review  reported on Tuesday.The offering is said to be cornerstoned by a global healthcare investor, the report said.The firm requested a halt in trading of its shares from the open of trading on Tuesday in connection with a proposed material capital raising, according to a same-day Australian bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","EQR","BK4215","AFR.AU","BK4585","BK4588","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638563526","title":"BRIEF-Tetratherix Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2638563526","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638563526?lang=en_us&edition=fundamental","pubTime":"2026-05-26 07:39","pubTimestamp":1779752344,"startTime":"0","endTime":"0","summary":"BRIEF-Tetratherix Requests Trading HaltMay 26 (Reuters) - Tetratherix Ltd TTX.AX:REQUESTS TRADING HALT FOR PROPOSED MATERIAL CAPITAL RAISINGFurther company coverage: TTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nFWN4220EA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637393437","title":"A AU$90m Market Cap Boost Pleasing ToTetratherix Insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2637393437","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637393437?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:55","pubTimestamp":1779422149,"startTime":"0","endTime":"0","summary":"Insiders who bought Tetratherix Limited ( ASX:TTX ) stock in the last 12 months were richly rewarded last week. The...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ttx/tetratherix-shares/news/a-au90m-market-cap-boost-pleasing-totetratherix-insiders","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ttx/tetratherix-shares/news/a-au90m-market-cap-boost-pleasing-totetratherix-insiders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619345326","title":"Tetratherix Launches Precision Medicine Franchise, Signs $3 Million-a-Year Deal With Superpower Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2619345326","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619345326?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:39","pubTimestamp":1773650344,"startTime":"0","endTime":"0","summary":"Tetratherix said it has launched a new precision medicine franchise leveraging its Tetramatrix platform polymer, according to a Monday Australian bourse filing.The company said the franchise will be immediately revenue-generating via an exclusive research and development agreement with US consumer health group Superpower Health, which will pay Tetratherix an exclusive licence payment of $3 million per year for up to 10 years.Under the agreement, Superpower will also purchase Tetramatrix platform polymer, branded as STEPP, for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides, and hormones in the US market, the filing added.The company said the precision medicine franchise is entirely additive to its existing business, with revenue generated under the agreement expected to strengthen its cash position without diverting resources from core programs, which are funded through to the start of fiscal 2028.Tetratherix continues to expect two FDA approvals in its bone","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619436377","title":"ASX Today: RBA call looming, Iran War unchanged, gold @ US$5K flat – so XJO errs on side of caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2619436377","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619436377?lang=en_us&edition=fundamental","pubTime":"2026-03-16 12:41","pubTimestamp":1773636060,"startTime":"0","endTime":"0","summary":"Greetings and welcome toHotCopper’s TheASX Today, I’m Jon Davidson, and while the XJO tried to break green at lunch, it couldn’t quite get there. Heading into the latter half of arvo trades, we’re down half a percent in the face of tomorrow’s widely expected RBA rate hike, gold dipping back to $5,000 an ounce flat USD, oil spiking above US$100/bbl, and a general sense of uncertainty.I said it last week, and I’ll say it again: Chaos reigns. While the ASX 200 is up +10% on a one-year basis, the bourse has lost nearly -4% over the last month. Retail participation in oil markets is at record highs, an obvious source of competition for gold, which, since the war, has gone down when oil goes up.Finally, CY25 IPO darling Tetratherix , which develops products to heal skin after surgery, as well as boasting other early-stage products looking at bone and skin grafts, has announced an interesting pivot on Monday. The company now wants to move into nasal-spray-delivered GLP-1 drugs, to use pub lan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"markerherald_stock","url":"https://themarketonline.com.au/asx-today-rba-call-looming-iran-war-unchanged-gold-us5k-flat-so-xjo-errs-on-side-of-caution-2026-03-16/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-today-rba-call-looming-iran-war-unchanged-gold-us5k-flat-so-xjo-errs-on-side-of-caution-2026-03-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IAU","AAAU","BK7507","BK4207","GDX","BK7067","TTX.AU","DZZ","GDXD","WHC.AU","A1N.AU","DYL.AU","GLL","IAUM","DUST","SGOL","BK7083","BK7509","BK4585","PDN.AU","DGP","GDXJ","BK4535","BK4504","XME","GLDM","AEE.AU","BOE.AU","BK4588","BK7052","JNUG","PEN.AU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619448712","title":"This asx biotech company has piled on more than 25% after a big announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2619448712","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619448712?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:54","pubTimestamp":1773626081,"startTime":"0","endTime":"0","summary":"Shares in Tetratherix Ltd (ASX: TTX) have surged more than 25% in early trade after the company announced a deal which could earn it more than US$30 million over the next 10 years.  The drug developme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/16/this-asx-biotech-company-has-piled-on-more-than-25-after-a-big-announcement/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619570484","title":"Tetratherix, which focuses on post-surgery skin healing, eyes new product: Nasal Ozempic","url":"https://stock-news.laohu8.com/highlight/detail?id=2619570484","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619570484?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:43","pubTimestamp":1773621780,"startTime":"0","endTime":"0","summary":"Tetratherix  is pivoting into one interesting class of biotech product well outside its existing focus on skin healing product TetraDerm for use following surgery – it wants to bring nasal GLP-1 drugs to market.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week.On Spotify, Apple, and more.If that sounds familiar, yes, we’re talking about the class of drugs that Ozempic made famous – next-gen weight loss medication that doesn’t involve anything that boosts your heart rate. And Tetratherix wants to make it a nasal delivery system. In other words, Ozempic for the nose.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"markerherald_stock","url":"https://themarketonline.com.au/tetratherix-which-focuses-on-post-surgery-skin-healing-eyes-new-product-nasal-ozempic-2026-03-16/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/tetratherix-which-focuses-on-post-surgery-skin-healing-eyes-new-product-nasal-ozempic-2026-03-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619048160","title":"BUZZ-Australia's Tetratherix rises on nasal delivery deal of GLP-1 in US market","url":"https://stock-news.laohu8.com/highlight/detail?id=2619048160","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619048160?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:07","pubTimestamp":1773619634,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Tetratherix rises on nasal delivery deal of GLP-1 in US market** Shares of Tetratherix TTX.AX rise as much as 21.6% to A$5.060, logging their biggest intraday session** The clinical products co signs a research & development agreement with health start-up Superpower Health ** Under deal, Superpower to pay TTX license payment of $3 million per year for up to 10 years** Co adds that Superpower to buy co's platform polymer, branded as STEPP, for nasal delivery of GLP-1s, peptides, and hormones in the U.S. market** Stock hits its highest level since October 21** Stock up over 54% this year, including the day's move  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL4N403083:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618600004","title":"Tetratherix Says Joint Venture Partner Completes Series A Funding Round to Progress Prostate Spacing Clinical Trial, Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600004","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618600004?lang=en_us&edition=fundamental","pubTime":"2026-03-10 12:03","pubTimestamp":1773115408,"startTime":"0","endTime":"0","summary":"Tetratherix  said its joint venture partner, Tutelix, completed a Series A funding round from key investors led by a MedTech venture capital firm, bringing the total funds raised by the joint venture to around AU$5 million, allowing the joint venture to fasttrack the prostate spacing clinical trial to move towards an international pivotal study in the Australia and the US, according to a Tuesday Australian bourse filing.The trial was designed to investigate the ability of the Tutelix spacer to be safely injected between the prostate and rectum to create and maintain space around the prostate.Around 12 patients included the Tutelix spacer in their treatment, with the space generated by the spacer reducing the radiation dose received by the rectum in each patient. All 12 participants completed or are in the process of completing their radiation treatment plans.Its shares jumped 5% in recent trading on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRGS","BK4185","BK7067","BK4097","JYNT","LU2065732104.USD","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}